GlassScriptPhysician profile
Nathan M Kakish
NPI 1518975309
$40,126.43
in general payments reported to CMS, 2019-2025
33 companies · $2,786 in 2025
The $2,786 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,644 · 2020: $867 · 2021: $1,377 · 2022: $811 · 2023: $5,139 · 2024: $25K · 2025: $2,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $4,156 · Travel and Lodging: $3,478 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,503.50 |
| Food and Beverage | $4,155.70 |
| Travel and Lodging | $3,477.53 |
| Education | $290.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,549.51 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $2,458.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,163.73 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,131.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $906.13 | 2019-2025 | |
| Lilly USA, LLC | $584.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $557.35 | 2019-2020 | |
| Amarin Pharma, INC. | $423.52 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $314.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.00 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.91 | 2019-2020 | |
| Pfizer INC. | $168.34 | 2019-2020 | |
| Medtronic, INC. | $165.73 | 2025 | Signia |
| Abbott Laboratories | $153.83 | 2022-2025 | Freestyle Libre 3 |
| Celgene Corporation | $140.21 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $125.96 | 2025 | Jetstream Sc |
| Eisai INC. | $116.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.74 | 2022 | |
| Sunovion Pharmaceuticals INC. | $92.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $85.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $81.97 | 2021 | |
| Mylan Specialty L.P. | $79.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.95 | 2019 | |
| Abbvie INC. | $27.25 | 2021 | |
| Shire North American Group INC | $26.81 | 2019 | |
| Allergan, INC. | $22.53 | 2019-2020 | |
| Phadia US INC. | $19.93 | 2021 | |
| Angiodynamics, INC. | $19.17 | 2019 | |
| Genentech USA, INC. | $16.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.09 | 2019 | |
| Sanofi Pasteur INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Kakish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.